Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

U.S. stocks are holding nearly in place as Wall Street waits to hear where the Federal Reserve may be taking interest rates. The S&P 500 was little changed early Wednesday. The Dow Jones Industrial ...

Solar stocks tumbled after Senate Republicans maintained a full phase-out of [solar and wind-energy tax credits]( ...

NEW YORK (AP) — U.S. stocks are nudging lower on Tuesday, and oil prices are rising again. It’s a modest return to form for ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.

Oil demand will peak at 105.6 million barrels per day (bpd) by 2029 and then fall slightly in 2030, a table in the Paris-based IEA’s annual report shows. At the same time, global production capacity ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an ...

The global market for diabetes drugs used for treating obesity is expected to expand in Asia, as new players jostle with giants Eli Lilly and Novo ... in China and Japan, where penetration is ...

Eli Lilly & Co. shares surged after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of ...

TOKYO -- U.S. drugmaker Eli Lilly has released its Zepbound obesity medication in Japan, targeting the millions said to suffer from the "hidden" scourge of buildups of visceral fat. "We believe ...